The company, in collaboration with CSL Limited, is leveraging research conducted at the University of Melbourne to develop a vaccine targeting the virulence factors produced by the bacterium Porphyromonas gingivalis and related species responsible for various periodontal diseases. By utilizing this vaccine, Denteric aims to assist patients in preventing dental diseases and their associated complications. The funding for this project will be received in three installments annually from 2019 to 2021.